Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions

被引:30
作者
Cwynarski, K [1 ]
Goulding, R
Pocock, C
Dazzi, F
Craddock, C
Kaeda, J
Olavarria, E
Kanfer, E
Apperley, J
Lawler, M
Goldman, JM
机构
[1] Hammersmith Hosp, Dept Haematol, ICSM, London W12 0NN, England
[2] St James Hosp, Dept Haematol, Sir Patrick Dun Res Labs, Dublin 8, Ireland
关键词
haemolytic anaemia; T cell depletion; chronic myeloid leukaemia; relapse; donor lymphocyte infusion;
D O I
10.1038/sj.bmt.1703206
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Immune haemolytic anaemia (IHA) is a recognised complication after allogeneic stem cell transplantation (SCT) and occurs more frequently if marrow cells have been subjected to T cell depletion (TCD). Among 58 consecutive patients who underwent TCD-allogeneic SCT from volunteer unrelated donors for the treatment of CML at the Hammersmith Hospital during a 3-year period (1 March 1996 to 28 February 1999) we identified nine cases of IHA. All patients had a strongly positive direct and indirect antiglobulin test and in eight patients the serological findings were typical of warm-type haemolysis often with antibody specificities within the Rh system. All nine cases had clinically significant haemolysis and were treated initially with prednisolone and immunoglobulin. The onset of IRA coincided with the occurrence of leukaemic relapse in six cases, and the presence of host haemopoiesis confirmed by lineage-specific chimerism in all four cases studied. Five patients received donor lymphocyte infusions (DLI); in three molecular remission and the restoration of full donor chimerism coincided with resolution of haemolysis. We conclude that in the context of leukaemic relapse, DLI is an effective therapy for IHA following allografts involving TCD.
引用
收藏
页码:581 / 586
页数:6
相关论文
共 35 条
[21]  
KLUMPP TR, 1991, BONE MARROW TRANSPL, V8, P159
[22]   GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS [J].
KOLB, HJ ;
SCHATTENBERG, A ;
GOLDMAN, JM ;
HERTENSTEIN, B ;
JACOBSEN, N ;
ARCESE, W ;
LJUNGMAN, P ;
FERRANT, A ;
VERDONCK, L ;
NIEDERWIESER, D ;
VANRHEE, F ;
MITTERMUELLER, J ;
DEWITTE, T ;
HOLLER, E ;
ANSARI, H .
BLOOD, 1995, 86 (05) :2041-2050
[23]  
LAWLER M, 1991, BLOOD, V77, P2504
[24]   Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation [J].
Lin, F ;
vanRhee, F ;
Goldman, JM ;
Cross, NCP .
BLOOD, 1996, 87 (10) :4473-4478
[25]   AGE, THYMOPOIESIS, AND CD4+ T-LYMPHOCYTE REGENERATION AFTER INTENSIVE CHEMOTHERAPY [J].
MACKALL, CL ;
FLEISHER, TA ;
BROWN, MR ;
ANDRICH, MP ;
CHEN, CC ;
FEUERSTEIN, IM ;
HOROWITZ, ME ;
MAGRATH, IT ;
SHAD, AT ;
STEINBERG, SM ;
WEXLER, LH ;
GRESS, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (03) :143-149
[26]  
MACKINNON S, 1994, BLOOD, V83, P3409
[27]   Control of immune pathology by regulatory T cells [J].
Mason, D ;
Powrie, F .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (06) :649-655
[28]  
MOLLER G, 1990, IMMUNOL REV, V118, P1
[29]  
ROUX E, 1993, BLOOD, V81, P243
[30]   Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion [J].
Sehn, LH ;
Alyea, EP ;
Weller, E ;
Canning, C ;
Lee, S ;
Ritz, J ;
Antin, JH ;
Soiffer, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :561-568